Ocugen (OCGN) said Wednesday that the European Medicines Agency has granted orphan medicinal product designation for its experimental drug OCU410ST to treat ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.
Orphan medicinal product designation in Europe provides benefits such as protocol assistance, reduced fees, research grants, and 10 years of market exclusivity upon approval.
The drug developer said it plans to pursue an accelerated marketing authorization application for OCU410ST.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。